Page 37 - Noble-Virtual-Healthcare-2024

Kiora Pharmaceuticals, Inc.

SELECTED FINANCIAL ITEMS KPRX

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit (0.44) (1.39) (1.09) (1.11) (4.03)
Gross Margin NM NM NM NM NM
EBIT (1.71) (2.49) (2.50) (1.99) (8.69)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (1.87) (2.61) (5.76) (2.27) (12.51)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 16.53 19.88 15.90 13.71 13.71
Cash & Short Term Investments 3.43 7.95 5.40 2.45 2.45
% of Assets 21% 40% 34% 18% 18%
Current Assets -Total 5.62 9.02 6.98 4.74 4.74
% of Assets 34% 45% 44% 35% 35%
Total Liabilities 6.37 6.24 7.79 7.60 7.60
% of Assets 39% 31% 49% 55% 55%
Current Liabilities - Total 2.16 1.88 2.10 1.63 1.63
% of Assets 13% 9% 13% 12% 12%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 10.16 13.64 8.10 6.11 6.11
% of Assets 61% 69% 51% 45% 45%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.07) (1.38) (2.52) (2.58) (9.56)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 0.51 5.94 0.00 (0.49) 5.97

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference